Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials

被引：20
作者：
Cabibbo, Giuseppe [1 ]
Cucchetti, Alessandro [2 ,3 ,4 ]
Camma, Calogero [1 ]
Casadei-Gardini, Andrea [4 ]
Celsa, Ciro [1 ]
Rizzo, Giacomo Emanuele Maria [1 ]
Johnson, Philip [5 ]
Ercolani, Giorgio [2 ,3 ]
机构：
[1] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Sect Gastroenterol & Hepatol, PROMISE, Palermo, Italy
[2] Univ Bologna, Dept Med & Surg Sci DIMEC, Bologna, Italy
[3] Univ Bologna, Alma Mater Studiorum, Bologna, Italy
[4] Univ Modena, Dept Med & Surg Sci Children & Adults, Div Med Oncol, Policlin Modena Azienda Osped, Modena, Italy
[5] Univ Liverpool, Dept Mol & Clin Canc Med, Duncan Bldg,Daulby St, Liverpool, Merseyside, England
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 29期
关键词：
hepatocellular carcinoma; meta-regression; sorafenib; survival; systemic therapy; time to progression; RANDOMIZED CLINICAL-TRIALS; DOUBLE-BLIND; SURVIVAL; EFFICACY; THERAPY; CANCER; SAFETY;
D O I：
10.2217/fon-2019-0287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan-Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6-10.5), and median TTP was 4.1 months (95% CI: 3.8-4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results can be used in the decision making for the early shift to second-line strategy.
引用
收藏
页码：3411 / 3422
页数：12
相关论文
共 41 条
[1]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[2]   Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding:: A meta-analysis [J].
Bañares, R ;
Albillos, A ;
Rincón, D ;
Alonso, S ;
González, M ;
Ruiz-del-Arbol, L ;
Salcedo, M ;
Molinero, LM .
HEPATOLOGY, 2002, 35 (03) :609-615
[3]   Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies [J].
Bruix, Jordi ;
Cheng, Ann-Lii ;
Meinhardt, Gerold ;
Nakajima, Keiko ;
De Sanctis, Yoriko ;
Llovet, Josep .
JOURNAL OF HEPATOLOGY, 2017, 67 (05) :999-1008
[4]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[5]   Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients [J].
Cabibbo, Giuseppe ;
Celsa, Ciro ;
Calvaruso, Vincenza ;
Petta, Salvatore ;
Cacciola, Irene ;
Cannavo, Maria Rita ;
Madonia, Salvatore ;
Rossi, Margherita ;
Magro, Bianca ;
Ini, Francesca ;
Distefano, Marco ;
Larocca, Licia ;
Prestileo, Tullio ;
Malizia, Giuseppe ;
Bertino, Gaetano ;
Benanti, Francesco ;
Licata, Anna ;
Scalisi, Ignazio ;
Mazzola, Giovanni ;
Di Rosolini, Maria Antonietta ;
Alaimo, Giuseppe ;
Averna, Alfonso ;
Cartabellotta, Fabio ;
Alessi, Nicola ;
Guastella, Salvatore ;
Russello, Maurizio ;
Scifo, Gaetano ;
Squadrito, Giovanni ;
Raimondo, Giovanni ;
Trevisani, Franco ;
Craxi, Antonio ;
Di Marco, Vito S. ;
Camma, Calogero .
JOURNAL OF HEPATOLOGY, 2019, 71 (02) :265-273
[6]   Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? [J].
Cabibbo, Giuseppe ;
Celsa, Ciro ;
Camma, Calogero ;
Craxi, Antonio .
LIVER INTERNATIONAL, 2018, 38 (12) :2108-2116
[7]   A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma [J].
Cabibbo, Giuseppe ;
Petta, Salvatore ;
Barbara, Marco ;
Missale, Gabriele ;
Virdone, Roberto ;
Caturelli, Eugenio ;
Piscaglia, Fabio ;
Morisco, Filomena ;
Colecchia, Antonio ;
Farinati, Fabio ;
Giannini, Edoardo ;
Trevisani, Franco ;
Craxi, Antonio ;
Colombo, Massimo ;
Camma, Calogero .
LIVER INTERNATIONAL, 2017, 37 (08) :1157-1166
[8]   Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma [J].
Cabibbo, Giuseppe ;
Petta, Salvatore ;
Barbara, Marco ;
Attardo, Simona ;
Bucci, Laura ;
Farinati, Fabio ;
Giannini, Edoardo G. ;
Negrini, Giulia ;
Ciccarese, Francesca ;
Rapaccini, Gian Lodovico ;
Di Marco, Maria ;
Caturelli, Eugenio ;
Zoli, Marco ;
Borzio, Franco ;
Sacco, Rodolfo ;
Virdone, Roberto ;
Marra, Fabio ;
Mega, Andrea ;
Morisco, Filomena ;
Benvegnu, Luisa ;
Gasbarrini, Antonio ;
Svegliati-Baroni, Gianluca ;
Foschi, Francesco Giuseppe ;
Olivani, Andrea ;
Masotto, Alberto ;
Nardone, Gerardo ;
Colecchia, Antonio ;
Persico, Marcello ;
Craxi, Antonio ;
Trevisani, Franco ;
Camma, Calogero .
JOURNAL OF HEPATOLOGY, 2017, 67 (01) :65-71
[9]   A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma [J].
Cabibbo, Giuseppe ;
Enea, Marco ;
Attanasio, Massimo ;
Bruix, Jordi ;
Craxi, Antonio ;
Camma, Calogero .
HEPATOLOGY, 2010, 51 (04) :1274-1283
[10]   Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial [J].
Cainap, Calin ;
Qin, Shukui ;
Huang, Wen-Tsung ;
Chung, Ik Joo ;
Pan, Hongming ;
Cheng, Ying ;
Kudo, Masatoshi ;
Kang, Yoon-Koo ;
Chen, Pei-Jer ;
Toh, Han-Chong ;
Gorbunova, Vera ;
Eskens, Ferry A. L. M. ;
Qian, Jiang ;
McKee, Mark D. ;
Ricker, Justin L. ;
Carlson, Dawn M. ;
El-Nowiem, Saied .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) :172-U77
12345